Study S001160

The SEMAFOOT2 Pilot Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07581145
Acronym: SEMAFOOT2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 52
Start: 2026-04-24
Primary completion: 2028-12
Lead sponsor: Ole Lander Svendsen
Conditions: Foot Ulcer Due to Type 2 Diabetes Mellitus
Interventions: DRUG:Semaglutide, 1.34 mg/mL; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2023-504913-65-01; OTHER:U1111-1282-3930; NIH:2023

Registered primary outcomes

Proportion of clinical healed index foot ulcer at week 20 [20 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.